(Q46681664)

24 December 2017

title

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development (English)

1 reference

24 December 2017

1 reference

7

1 reference

24 December 2017

Andreas Hochhaus

9

1 reference

24 December 2017

author name string

Burchert A

1

1 reference

24 December 2017

Wang Y

2

1 reference

24 December 2017

Cai D

3

1 reference

24 December 2017

von Bubnoff N

4

1 reference

24 December 2017

Paschka P

5

1 reference

24 December 2017

Müller-Brüsselbach S

6

1 reference

24 December 2017

Duyster J

8

1 reference

24 December 2017

Neubauer A

10

1 reference

24 December 2017

publication date

1 October 2005

1 reference

24 December 2017

published in

Leukemia

1 reference

24 December 2017

volume

19

1 reference

24 December 2017

page(s)

1774-1782

1 reference

24 December 2017

issue

10

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403898

exact match

0 references

cites work

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Roots of clinical resistance to STI-571 cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Analysis of Gene Expression Profiles in an Imatinib‐Resistant Cell Line, KCL22/SR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

PDK1 regulates growth through Akt and S6K in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Phosphorylation and activation of p70s6k by PDK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Will mTOR inhibitors make it as cancer drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Targeting mTOR signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Antileukemic activity of rapamycin in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Determinants of rapamycin sensitivity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

DNA CONTENTS OF CHROMOSOME PH1 AND CHROMOSOME 21 IN HUMAN CHRONIC GRANULOCYTIC LEUKEMIA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403898

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403898

1 reference

24 December 2017

PubMed ID

16136169

1 reference

24 December 2017